These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27495122)

  • 1. Targeting bactoprenol-coupled cell envelope precursors.
    Ulm H; Schneider T
    Appl Microbiol Biotechnol; 2016 Sep; 100(18):7815-25. PubMed ID: 27495122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid II and other bactoprenol-bound cell wall precursors as drug targets.
    Schneider T; Sahl HG
    Curr Opin Investig Drugs; 2010 Feb; 11(2):157-64. PubMed ID: 20112165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid II as a target for antibiotics.
    Breukink E; de Kruijff B
    Nat Rev Drug Discov; 2006 Apr; 5(4):321-32. PubMed ID: 16531990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Found Hope for Antibiotic Discovery: Lipid II Inhibitors.
    Ng V; Chan WC
    Chemistry; 2016 Aug; 22(36):12606-16. PubMed ID: 27388768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting a cell wall biosynthesis hot spot.
    Müller A; Klöckner A; Schneider T
    Nat Prod Rep; 2017 Jul; 34(7):909-932. PubMed ID: 28675405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docking on Lipid II-A Widespread Mechanism for Potent Bactericidal Activities of Antibiotic Peptides.
    Grein F; Schneider T; Sahl HG
    J Mol Biol; 2019 Aug; 431(18):3520-3530. PubMed ID: 31100388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
    Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
    Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate.
    Schneider T; Gries K; Josten M; Wiedemann I; Pelzer S; Labischinski H; Sahl HG
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1610-8. PubMed ID: 19164139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway.
    Schneider T; Sahl HG
    Int J Med Microbiol; 2010 Feb; 300(2-3):161-9. PubMed ID: 20005776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding role of lipid II as a target for lantibiotics.
    Martin NI; Breukink E
    Future Microbiol; 2007 Oct; 2(5):513-25. PubMed ID: 17927474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Synthesis of Laspartomycin C and Characterization of Its Antibacterial Mechanism of Action.
    Kleijn LH; Oppedijk SF; 't Hart P; van Harten RM; Martin-Visscher LA; Kemmink J; Breukink E; Martin NI
    J Med Chem; 2016 Apr; 59(7):3569-74. PubMed ID: 26967152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural variations of the cell wall precursor lipid II in Gram-positive bacteria - Impact on binding and efficacy of antimicrobial peptides.
    Münch D; Sahl HG
    Biochim Biophys Acta; 2015 Nov; 1848(11 Pt B):3062-71. PubMed ID: 25934055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting extracellular pyrophosphates underpins the high selectivity of nisin.
    Bonev BB; Breukink E; Swiezewska E; De Kruijff B; Watts A
    FASEB J; 2004 Dec; 18(15):1862-9. PubMed ID: 15576489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the Binding Interactions of Teixobactin with the Bacterial Cell-Wall Precursor Lipid II.
    Chiorean S; Antwi I; Carney DW; Kotsogianni I; Giltrap AM; Alexander FM; Cochrane SA; Payne RJ; Martin NI; Henninot A; Vederas JC
    Chembiochem; 2020 Mar; 21(6):789-792. PubMed ID: 31552694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hit 'em where it hurts: The growing and structurally diverse family of peptides that target lipid-II.
    Oppedijk SF; Martin NI; Breukink E
    Biochim Biophys Acta; 2016 May; 1858(5):947-57. PubMed ID: 26523408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity exploration of a small-molecule Lipid II inhibitor.
    Fletcher S; Yu W; Huang J; Kwasny SM; Chauhan J; Opperman TJ; MacKerell AD; de Leeuw E
    Drug Des Devel Ther; 2015; 9():2383-94. PubMed ID: 25987836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregates of nisin with various bactoprenol-containing cell wall precursors differ in size and membrane permeation capacity.
    Scherer K; Wiedemann I; Ciobanasu C; Sahl HG; Kubitscheck U
    Biochim Biophys Acta; 2013 Nov; 1828(11):2628-36. PubMed ID: 23872123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-resistance mechanisms of actinomycetes producing lipid II-targeting antibiotics.
    Stegmann E; Frasch HJ; Kilian R; Pozzi R
    Int J Med Microbiol; 2015 Feb; 305(2):190-5. PubMed ID: 25601631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of bacteria adhesion by cell-wall engineering.
    Sadamoto R; Niikura K; Ueda T; Monde K; Fukuhara N; Nishimura S
    J Am Chem Soc; 2004 Mar; 126(12):3755-61. PubMed ID: 15038728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.
    de Kruijff B; van Dam V; Breukink E
    Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):117-21. PubMed ID: 19008088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.